{"filing":{"accession_number":"0001193125-26-352208","cik":"0001620463","ticker":"LONA","company_name":"LeonaBio, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"lona-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526352208/lona-20260814.htm"},"events":[{"id":27890,"run_id":25467,"accession_number":"0001193125-26-352208","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"LeonaBio issued a press release on August 14, 2026 reporting Q2 2026 financial results, including cash position of $51.1M, R\u0026D expenses of $12.9M, G\u0026A expenses of $6.6M, and net loss of $19.0M ($0.80 per share), along with a business update on Phase 3 ELAINE-3 clinical trial enrollment progress and pipeline programs.","company_name":"LeonaBio, Inc.","ticker":"LONA","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29603,"accession_number":"0001193125-26-352208","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LeonaBio issued a press release on August 14, 2026 reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 cash position ($51.1M), R\u0026D expenses ($12.9M), G\u0026A expenses ($6.6M), and net loss ($19.0M or $0.80 per share). The filing includes condensed consolidated balance sheets and statements of operations, which are standard components of quarterly earnings disclosures. This is a classic Item 2.02 earnings release for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:21.101992+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29604,"accession_number":"0001193125-26-352208","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LeonaBio disclosed Q2 2026 financial results (cash position, R\u0026D expenses, G\u0026A expenses, and net loss) via press release attached as EX-99.1, along with a business update on its Phase 3 ELAINE-3 clinical trial enrollment progress and pipeline programs. This is a standard earnings release disclosure under Item 7.01 (Regulation FD Disclosure), reporting quarterly financial results and operational milestones material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:21.101992+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29603,"accession_number":"0001193125-26-352208","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LeonaBio issued a press release on August 14, 2026 reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 cash position ($51.1M), R\u0026D expenses ($12.9M), G\u0026A expenses ($6.6M), and net loss ($19.0M or $0.80 per share). The filing includes condensed consolidated balance sheets and statements of operations, which are standard components of quarterly earnings disclosures. This is a classic Item 2.02 earnings release for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:21.101992+00:00","company_name":"LeonaBio, Inc.","ticker":"LONA","filing_date":"2026-08-14"},{"id":29604,"accession_number":"0001193125-26-352208","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"LeonaBio disclosed Q2 2026 financial results (cash position, R\u0026D expenses, G\u0026A expenses, and net loss) via press release attached as EX-99.1, along with a business update on its Phase 3 ELAINE-3 clinical trial enrollment progress and pipeline programs. This is a standard earnings release disclosure under Item 7.01 (Regulation FD Disclosure), reporting quarterly financial results and operational milestones material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:20:21.101992+00:00","company_name":"LeonaBio, Inc.","ticker":"LONA","filing_date":"2026-08-14"}]}